Dicerna Pharmaceuticals Company Profile (NASDAQ:DRNA)

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers, including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET).

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: DRNA
CUSIP:

Key Metrics:

Previous Close: $5.88
50 Day Moving Average: $3.58
200 Day Moving Average: $3.90
52-Week Range: $2.69 - $15.93
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -2.13
P/E Growth: 0.00
Market Cap: $122.03M
Outstanding Shares: 20,753,000
Beta: 2.28

Profitability:

Return on Equity: -75.52%
Return on Assets: -68.42%

Debt:

Current Ratio: 7.55%
Quick Ratio: 7.55%

Additional Links:

Companies Related to Dicerna Pharmaceuticals:

Consensus Ratings for Dicerna Pharmaceuticals (NASDAQ:DRNA) (?)

Ratings Breakdown:	1 Hold Rating, 4 Buy Ratings
Consensus Rating:	Buy (Score: 2.80)
Consensus Price Target:	$13.88 (135.97% upside)

Analysts' Ratings History for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Show:

Date	Firm	Action	Rating	Price Target
9/28/2016	Stifel Nicolaus	Reiterated Rating	Buy	$13.00
8/15/2016	Chardan Capital	Lower Price Target	Neutral	$4.00 -> $3.50
8/5/2016	Cowen and Company	Reiterated Rating	Buy
6/30/2016	Leerink Swann	Reiterated Rating	Buy
5/10/2016	Jefferies Group	Reiterated Rating	Buy	$19.00

(Data available from 9/30/2014 forward)

Earnings History for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Release Link	Conference Call
11/8/2016
8/4/2016	Q216	($0.84)	($0.75)		View	N/A
5/9/2016	Q116	($0.86)	($0.76)		View	N/A
3/10/2016	Q415	($0.84)	($0.76)		View	Listen
11/10/2015	Q315	($0.84)	($0.82)		View	Listen
8/6/2015	Q215	($0.78)	($0.86)		View	N/A
5/11/2015	Q1	($0.73)	($0.79)	$600.00 million	View	Listen
3/12/2015	Q414	($0.57)	($0.57)	$1.45 million	View	N/A
11/6/2014		($0.63)	($0.63)		View	N/A
8/7/2014		($0.47)	($0.64)		View	N/A
5/13/2014	Q114	($0.52)	($1.02)		View	N/A
3/27/2014		($0.62)	($0.20)		View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Current Year EPS Consensus Estimate: $-3.17 EPS
Next Year EPS Consensus Estimate: $-2.76 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q2 2016	2	($0.92)	($0.85)	($0.89)
Q3 2016	2	($0.97)	($0.94)	($0.96)
Q4 2016	2	($1.07)	($1.07)	($1.07)

(Data provided by Zacks Investment Research)

Dividend History for Dicerna Pharmaceuticals (NASDAQ:DRNA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Insider Ownership Percentage: 27.65%
Institutional Ownership Percentage: 62.38%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
5/12/2016	James B Weissman	Insider	Buy	5,000	$3.29	$16,450.00
11/25/2014	James E Flynn	Insider	Sell	321,965	$11.36	$3,657,522.40
11/7/2014	James E Flynn	Insider	Sell	214,164	$9.05	$1,938,184.20
10/15/2014	James E Flynn	Insider	Sell	117,778	$10.86	$1,279,069.08
10/14/2014	James E Flynn	Major Shareholder	Sell	36,115	$11.02	$397,987.30
10/10/2014	James E Flynn	Major Shareholder	Sell	30,214	$12.13	$366,495.82
2/4/2014	James E Flynn	Insider	Buy	1,000,000	$15.00	$15,000,000.00
2/4/2014	Stephen J Hoffman	Director	Buy	200,000	$15.00	$3,000,000.00

(Data available from 1/1/2013 forward)

Latest Headlines for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Date	Headline
	Traders' Pick: Leading Gainers - QLT Inc. (NASDAQ: QLTI), Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA), Tidewater ... - FxPips.com (NASDAQ:DRNA) www.fxpips.com - September 30 at 9:45 AM
	Time To Put On The Watch List? - Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), 22nd Century Group, Inc ... - The Voice Registrar (NASDAQ:DRNA) voiceregistrar.com - September 30 at 9:45 AM
	Latest Analyst Ratings For Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) - The De Soto Edge (NASDAQ:DRNA) desotoedge.com - September 29 at 9:42 AM
	Dicerna Pharma (DRNA): Strategy Shift Should Yield LT Gains - Stifel - StreetInsider.com (NASDAQ:DRNA) www.streetinsider.com - September 28 at 4:34 PM
	Dicerna Prioritizes Resources to Advance GalXC Product Candidates (NASDAQ:DRNA) www.cbs58.com - September 27 at 9:15 AM
	Dicerna Pharmaceuticals : Prioritizes Resources to Advance GalXC™ Product Candidates (NASDAQ:DRNA) www.4-traders.com - September 26 at 9:23 AM
	7:31 am Dicerna Pharmaceuticals will focus its resources on its GalXC technology; will discontinue clinical development of DCR-MYC (NASDAQ:DRNA) finance.yahoo.com - September 26 at 9:23 AM
	Dicerna Prioritizes Resources to Advance GalXC™ Product Candidates (NASDAQ:DRNA) www.publicnow.com - September 26 at 9:23 AM
	Dicerna Pharmaceuticals Forecasted to Post FY2017 Earnings of ($4.55) Per Share (DRNA) - Petro Global News 24 (NASDAQ:DRNA) petroglobalnews24.com - September 23 at 4:29 PM
	Dicerna Pharmaceuticals (DRNA) Worth a Look: Stock Up 6% - Yahoo Finance (NASDAQ:DRNA) finance.yahoo.com - September 22 at 10:16 AM
	Dicerna Pharmaceuticals, Inc. :DRNA-US: Earnings Analysis: Q2, 2016 By the Numbers : September 21, 2016 (NASDAQ:DRNA) www.capitalcube.com - September 21 at 5:12 PM
	Earnings Analysis & Update for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)? - Frisco Fastball (NASDAQ:DRNA) friscofastball.com - September 14 at 4:46 PM
	Earnings Analysis & Update for Dicerna Pharmaceuticals, Inc ... - Frisco Fastball (NASDAQ:DRNA) friscofastball.com - September 14 at 4:46 PM
	Placing Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Shares Under the Microscope - National Daily Press (NASDAQ:DRNA) www.nationaldailypress.com - September 9 at 9:31 AM
	Dicerna to Present at September Investor Conferences (NASDAQ:DRNA) www.publicnow.com - September 6 at 4:35 PM
	How Analysts & Retail Investors Perceive Dicerna Pharmaceuticals ... - Post News (NASDAQ:DRNA) www.kentuckypostnews.com - August 21 at 9:13 AM
	Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 7.5% - Nasdaq (NASDAQ:DRNA) www.nasdaq.com - August 17 at 7:37 AM
	Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 7.5% (NASDAQ:DRNA) finance.yahoo.com - August 16 at 4:46 PM
	DICERNA PHARMACEUTICALS INC Financials (NASDAQ:DRNA) finance.yahoo.com - August 13 at 4:38 PM
	My Watchlist for Monday, August 15 (NASDAQ:DRNA) ac-investor.blogspot.com - August 13 at 8:30 AM
	Dicerna Pharmaceuticals Inc. (DRNA) Jumps 6.58% on August 05 - Equities.com (NASDAQ:DRNA) www.equities.com - August 6 at 5:01 PM
	Edited Transcript of DRNA earnings conference call or presentation 4-Aug-16 8:30pm GMT (NASDAQ:DRNA) finance.yahoo.com - August 5 at 4:43 PM
	Dicerna Pharmaceuticals posts 2Q loss (NASDAQ:DRNA) sg.finance.yahoo.com - August 4 at 10:24 PM
	Dicerna Pharmaceuticals Inc.: Dicerna Reports Second Quarter 2016 Financial and Operational Results (NASDAQ:DRNA) www.twst.com - August 4 at 4:53 PM
	Dicerna Reports Second Quarter 2016 Financial and Operational Results (NASDAQ:DRNA) www.publicnow.com - August 4 at 4:53 PM
	Q2 2016 Dicerna Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:DRNA) biz.yahoo.com - August 4 at 8:30 AM
	Dicerna to Report Second Quarter 2016 Financial Results and Host Conference Call on August 4, 2016 (NASDAQ:DRNA) www.publicnow.com - July 28 at 4:28 PM
	Dicerna Pharmaceuticals Inc. (DRNA) Jumps 6.09% on July 27 - Equities.com (NASDAQ:DRNA) www.equities.com - July 27 at 10:22 PM
	Increased Stock Volatility Watch: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Engelwood Daily (NASDAQ:DRNA) www.engelwooddaily.com - July 21 at 8:09 AM
	Insiders Increasing Positions in: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Press Telegraph (NASDAQ:DRNA) presstelegraph.com - July 21 at 8:09 AM
	Dicerna Pharmaceuticals Inc. (DRNA) Drops 7.54% on July 19 - Equities.com (NASDAQ:DRNA) www.equities.com - July 21 at 8:09 AM
	Broker Outlook For Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) - Fiscal Standard (NASDAQ:DRNA) www.fiscalstandard.com - July 20 at 8:44 AM
	Heightened Volatility Spotted on Shares of: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Engelwood Daily (NASDAQ:DRNA) www.engelwooddaily.com - July 19 at 9:58 PM
	Dicerna Pharmaceuticals Inc. (DRNA) Jumps 5.29% on July 18 - Equities.com (NASDAQ:DRNA) www.equities.com - July 19 at 10:48 AM
	Shares Experiencing a Downtrend: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - TGP (NASDAQ:DRNA) telanaganapress.com - July 16 at 8:06 AM
	Increased Volatility Noted on Shares of: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Engelwood Daily (NASDAQ:DRNA) www.engelwooddaily.com - July 16 at 8:06 AM
	Dicerna Pharmaceuticals Inc. (DRNA) Jumps 7.26% on July 15 - Equities.com (NASDAQ:DRNA) www.equities.com - July 16 at 8:06 AM
	Crowd Rating and Earnings Recap for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Telanagana Press (NASDAQ:DRNA) telanaganapress.com - July 15 at 7:55 AM
	Dicerna Pharmaceuticals Inc. (DRNA) Drops 7.04% on July 13 - Equities.com (NASDAQ:DRNA) www.equities.com - July 14 at 10:09 PM
	Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Wall Street Analyst Recommendation Outlook - Telanagana Press (NASDAQ:DRNA) telanaganapress.com - July 14 at 4:55 PM
	Dicerna Pharmaceuticals Incorporated (NASDAQ:DRNA) Shorted Shares Increased By 5.33% - Press Telegraph (NASDAQ:DRNA) presstelegraph.com - July 14 at 6:18 AM
	Share Volatility Watch for: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Engelwood Daily (NASDAQ:DRNA) www.engelwooddaily.com - July 13 at 4:50 PM
	Dicerna Pharmaceuticals Inc's Stock Is Sell After Today's Huge Decline - Consumer Eagle (NASDAQ:DRNA) www.consumereagle.com - July 13 at 4:50 PM
	Dicerna Pharmaceuticals Inc Stock Momentum Hits Weakness - CML News (NASDAQ:DRNA) news.cmlviz.com - July 13 at 8:58 AM
	Why Making Dramatic Moves: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), BP p.l.c. (NYSE:BP), Pfizer Inc. (NYSE ... - KC Register (NASDAQ:DRNA) www.kcregister.com - July 13 at 8:58 AM
	Are Analysts Bullish Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) After Last Week? - Consumer Eagle (NASDAQ:DRNA) www.consumereagle.com - July 13 at 8:58 AM
	Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Institutional Investor Positioning - Consumer Eagle (NASDAQ:DRNA) www.consumereagle.com - July 13 at 8:58 AM
	Stock Volatility Focus for: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Engelwood Daily (NASDAQ:DRNA) www.engelwooddaily.com - July 11 at 4:42 PM
	Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:DRNA) www.engelwooddaily.com - July 11 at 4:42 PM
	DICERNA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:DRNA) biz.yahoo.com - July 11 at 4:02 PM